Single User License
INR 161450
Site License
INR 322900
Corporate User License
INR 484350

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015

Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015


  • Products Id :- GDHC2563CTIDB
  • |
  • Pages: 93
  • |
  • February 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015

GlobalData's clinical trial report, "Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015" provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Malignant Glioma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each

Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type

Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons To Buy

Understand the dynamics of a particular indication in a condensed manner

Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more

Obtain discontinued trial listing for trials across the globe

Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Recurrent Malignant Glioma 6

Report Guidance 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20

Clinical Trials by Phase 21

In Progress Trials by Phase 22

Clinical Trials by Trial Status 23

Clinical Trials by End Point Status 24

Unaccomplished Trials of Recurrent Malignant Glioma 25

Subjects Recruited Over a Period of Time 28

Clinical Trials by Sponsor Type 29

Prominent Sponsors 30

Top Companies Participating in Recurrent Malignant Glioma Therapeutics Clinical Trials 31

Prominent Drugs 32

Clinical Trial Profiles 33

Clinical Trial Overview of Top Companies 33

Merck & Co., Inc. 33

Clinical Trial Overview of Merck & Co., Inc. 33

INSYS Therapeutics, Inc. 34

Clinical Trial Overview of INSYS Therapeutics, Inc. 34

Eli Lilly and Company 35

Clinical Trial Overview of Eli Lilly and Company 35

Eisai Co., Ltd. 36

Clinical Trial Overview of Eisai Co., Ltd. 36

TransMolecular, Inc. 37

Clinical Trial Overview of TransMolecular, Inc. 37

Tactical Therapeutics, Inc 38

Clinical Trial Overview of Tactical Therapeutics, Inc 38

Shandong Lanjin Pharmaceuticals Co. Ltd 39

Clinical Trial Overview of Shandong Lanjin Pharmaceuticals Co. Ltd 39

Oncolytics Biotech Inc. 40

Clinical Trial Overview of Oncolytics Biotech Inc. 40

Amgen Inc. 41

Clinical Trial Overview of Amgen Inc. 41

Alkermes Plc 42

Clinical Trial Overview of Alkermes Plc 42

Clinical Trial Overview of Top Institutes / Government 43

National Cancer Institute 43

Clinical Trial Overview of National Cancer Institute 43

Duke University 45

Clinical Trial Overview of Duke University 45

Memorial Sloan Kettering Cancer Center 47

Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 47

North American Brain Tumor Consortium 48

Clinical Trial Overview of North American Brain Tumor Consortium 48

University of Texas M. D. Anderson Cancer Center 49

Clinical Trial Overview of University of Texas M. D. Anderson Cancer Center 49

Northwestern University 50

Clinical Trial Overview of Northwestern University 50

UCLA's Jonsson Comprehensive Cancer Center 51

Clinical Trial Overview of UCLA's Jonsson Comprehensive Cancer Center 51

City of Hope 52

Clinical Trial Overview of City of Hope 52

University of Colorado 53

Clinical Trial Overview of University of Colorado 53

Five Key Clinical Profiles 54

Appendix 91

Abbreviations 91

Definitions 91

Research Methodology 92

Secondary Research 92

About GlobalData 93

Contact Us 93

Disclaimer 93

Source 93

List of Figures

Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Region (%), 2015* 7

Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8

Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Recurrent Malignant Glioma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 10

Recurrent Malignant Glioma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11

Recurrent Malignant Glioma Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12

Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, G7 Countries (%), 2015* 15

Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16

Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17

Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, E7 Countries (%), 2015* 18

Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19

Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20

Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21

Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22

Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23

Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24

Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28

Recurrent Malignant Glioma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 29

Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30

Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31

Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32

GlobalData Methodology 92

List of Tables

Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Region, 2015* 7

Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8

Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Recurrent Malignant Glioma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 10

Recurrent Malignant Glioma Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11

Recurrent Malignant Glioma Therapeutics Clinical Trials, North America, Top Countries, 2015* 12

Recurrent Malignant Glioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13

Recurrent Malignant Glioma Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14

Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, G7 Countries (%), 2015* 15

Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16

Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17

Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, E7 Countries (%), 2015* 18

Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19

Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20

Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Phase, 2015* 21

Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22

Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23

Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24

Recurrent Malignant Glioma Therapeutics, Global, Suspended Clinical Trials, 2015* 25

Recurrent Malignant Glioma Therapeutics, Global, Withdrawn Clinical Trials, 2015* 26

Recurrent Malignant Glioma Therapeutics, Global, Terminated Clinical Trials, 2015* 27

Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28

Recurrent Malignant Glioma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 29

Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30

Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31

Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2015* 33

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by INSYS Therapeutics, Inc., 2015* 34

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2015* 35

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eisai Co., Ltd., 2015* 36

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by TransMolecular, Inc., 2015* 37

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Tactical Therapeutics, Inc, 2015* 38

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Shandong Lanjin Pharmaceuticals Co. Ltd, 2015* 39

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Oncolytics Biotech Inc., 2015* 40

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2015* 41

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Alkermes Plc, 2015* 42

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2015* 43

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2015* 45

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2015* 47

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by North American Brain Tumor Consortium, 2015* 48

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Texas M. D. Anderson Cancer Center, 2015* 49

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Northwestern University, 2015* 50

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by UCLA's Jonsson Comprehensive Cancer Center, 2015* 51

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by City of Hope, 2015* 52

Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Colorado, 2015* 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Recurrent Malignant Glioma Clinical Trials, Trial Designs, Subjects Recruited, Unaccomplished Trials of Recurrent Malignant Glioma, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas, M.D. Andersons, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, National Cancer Center, University of Pennsylvania.


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com